Does the media refer more to PTCT or UTHR?

In the previous week, United Therapeutics had 25 more articles in the media than PTC Therapeutics. MarketBeat recorded 41 mentions for United Therapeutics and 16 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 1.45 beat PTC Therapeutics' score of 1.23 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 32 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GMAB or PTCT more profitable?

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media favor GMAB or PTCT?

In the previous week, PTC Therapeutics had 11 more articles in the media than Genmab A/S. MarketBeat recorded 16 mentions for PTC Therapeutics and 5 mentions for Genmab A/S. PTC Therapeutics' average media sentiment score of 1.23 beat Genmab A/S's score of 0.98 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTCT or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat BridgeBio Pharma's score of 1.17 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or PTCT?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 16 articles in the media. PTC Therapeutics' average media sentiment score of 1.23 beat Ascendis Pharma A/S's score of 1.13 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, EXEL or PTCT?

Exelixis has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.54 $782.57M $3.18 17.12 PTC Therapeutics $1.73B 3.38 $682.64M -$0.58 N/A

Is EXEL or PTCT more profitable?

Exelixis has a net margin of 35.33% compared to PTC Therapeutics' net margin of -3.80%. Exelixis' return on equity of 42.17% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media prefer EXEL or PTCT?

In the previous week, Exelixis had 17 more articles in the media than PTC Therapeutics. MarketBeat recorded 33 mentions for Exelixis and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Exelixis' score of 1.14 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PTC Therapeutics (PTCT) Competitors

$70.09 -1.72 (-2.40%)

As of 08/28/2026 04:00 PM Eastern

Compare

PTCT vs. UTHR, GMAB, BBIO, ASND, and EXEL

Should you buy PTC Therapeutics stock or one of its competitors? PTC Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PTC Therapeutics compare to United Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, United Therapeutics had 25 more articles in the media than PTC Therapeutics. MarketBeat recorded 41 mentions for United Therapeutics and 16 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 1.45 beat PTC Therapeutics' score of 1.23 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	32 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to PTC Therapeutics' net margin of -3.80%. United Therapeutics' return on equity of 20.18% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
United Therapeutics	41.56%	20.18%	17.98%

United Therapeutics has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A
United Therapeutics	$3.18B	6.95	$1.33B	$27.95	18.44

PTC Therapeutics presently has a consensus price target of $98.55, indicating a potential upside of 40.60%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 25.32%. Given PTC Therapeutics' higher probable upside, equities research analysts clearly believe PTC Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

94.1% of United Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PTC Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

United Therapeutics beats PTC Therapeutics on 15 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genmab A/S currently has a consensus price target of $39.50, suggesting a potential upside of 18.87%. PTC Therapeutics has a consensus price target of $98.55, suggesting a potential upside of 40.60%. Given PTC Therapeutics' higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Genmab A/S has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$4.13B	5.02	$963M	$1.27	26.17
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A

In the previous week, PTC Therapeutics had 11 more articles in the media than Genmab A/S. MarketBeat recorded 16 mentions for PTC Therapeutics and 5 mentions for Genmab A/S. PTC Therapeutics' average media sentiment score of 1.23 beat Genmab A/S's score of 0.98 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Summary

Genmab A/S beats PTC Therapeutics on 11 of the 15 factors compared between the two stocks.

How does PTC Therapeutics compare to BridgeBio Pharma?

PTC Therapeutics (NASDAQ:PTCT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

PTC Therapeutics presently has a consensus price target of $98.55, indicating a potential upside of 40.60%. BridgeBio Pharma has a consensus price target of $100.79, indicating a potential upside of 31.58%. Given PTC Therapeutics' higher possible upside, research analysts clearly believe PTC Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

PTC Therapeutics has higher revenue and earnings than BridgeBio Pharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A
BridgeBio Pharma	$713.07M	21.00	-$724.93M	-$3.57	N/A

In the previous week, BridgeBio Pharma had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat BridgeBio Pharma's score of 1.17 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PTC Therapeutics has a net margin of -3.80% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
BridgeBio Pharma	-97.03%	N/A	-61.19%

PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

BridgeBio Pharma beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Ascendis Pharma A/S has a net margin of 70.99% compared to PTC Therapeutics' net margin of -3.80%. Ascendis Pharma A/S's return on equity of 32.54% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. PTC Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.99	-$258M	$12.89	19.23
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 16 articles in the media. PTC Therapeutics' average media sentiment score of 1.23 beat Ascendis Pharma A/S's score of 1.13 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S currently has a consensus price target of $302.68, suggesting a potential upside of 22.09%. PTC Therapeutics has a consensus price target of $98.55, suggesting a potential upside of 40.60%. Given PTC Therapeutics' higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Ascendis Pharma A/S beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PTC Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Exelixis presently has a consensus target price of $50.07, suggesting a potential downside of 8.05%. PTC Therapeutics has a consensus target price of $98.55, suggesting a potential upside of 40.60%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to PTC Therapeutics' net margin of -3.80%. Exelixis' return on equity of 42.17% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Exelixis has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.54	$782.57M	$3.18	17.12
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Exelixis had 17 more articles in the media than PTC Therapeutics. MarketBeat recorded 33 mentions for Exelixis and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Exelixis' score of 1.14 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.85B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-120.84	11.62	273.16	25.45
Price / Sales	3.38	1,295.87	605.06	76.64
Price / Cash	7.99	106.39	76.74	53.00
Price / Book	-35.40	16.53	12.98	6.14
Net Income	$682.64M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.39%	-0.31%	0.13%	-0.80%
1 Month Performance	-7.19%	9.80%	7.08%	4.13%
1 Year Performance	42.08%	55.66%	24.67%	15.17%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	3.7793 of 5 stars	$70.09 -2.4%	$98.55 +40.6%	+42.1%	$5.85B	$1.73B	N/A	1,410	News Coverage Positive News Insider Trade
UTHR United Therapeutics	4.7554 of 5 stars	$512.88 0.0%	$646.00 +26.0%	+69.1%	$22.01B	$3.18B	18.35	1,400	News Coverage Analyst Downgrade Insider Trade
GMAB Genmab A/S	3.9342 of 5 stars	$33.02 -1.3%	$39.50 +19.6%	+33.6%	$20.86B	$3.72B	26.00	3,029	Options Volume
BBIO BridgeBio Pharma	3.4598 of 5 stars	$81.07 -0.5%	$100.79 +24.3%	+48.0%	$15.93B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.7031 of 5 stars	$251.95 -0.5%	$300.33 +19.2%	+27.6%	$15.80B	$814.57M	19.55	1,189	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does PTC Therapeutics compare to United Therapeutics?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Summary

How does PTC Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does PTC Therapeutics compare to United Therapeutics?

Does the media refer more to PTCT or UTHR?

Is PTCT or UTHR more profitable?

Which has preferable earnings & valuation, PTCT or UTHR?

Do analysts prefer PTCT or UTHR?

Do institutionals and insiders believe in PTCT or UTHR?

Which has more volatility and risk, PTCT or UTHR?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Do insiders and institutionals hold more shares of GMAB or PTCT?

Do analysts rate GMAB or PTCT?

Which has more risk and volatility, GMAB or PTCT?

Which has better valuation & earnings, GMAB or PTCT?

Does the media favor GMAB or PTCT?

Is GMAB or PTCT more profitable?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Do analysts recommend PTCT or BBIO?

Which has stronger earnings & valuation, PTCT or BBIO?

Does the media refer more to PTCT or BBIO?

Do institutionals & insiders hold more shares of PTCT or BBIO?

Is PTCT or BBIO more profitable?

Which has more volatility and risk, PTCT or BBIO?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Is ASND or PTCT more profitable?

Which has more volatility and risk, ASND or PTCT?

Which has higher valuation and earnings, ASND or PTCT?

Does the media refer more to ASND or PTCT?

Do analysts prefer ASND or PTCT?

Summary

How does PTC Therapeutics compare to Exelixis?

Do analysts rate EXEL or PTCT?

Which has more risk & volatility, EXEL or PTCT?

Is EXEL or PTCT more profitable?

Which has preferable earnings & valuation, EXEL or PTCT?

Do insiders and institutionals hold more shares of EXEL or PTCT?

Does the media prefer EXEL or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools